Visszatérés

Szolgáltatásink az alábbi országokban elérhetőek

Corporate

Európa:

Zászló Albánia Albánia Zászló Bosznia Herzegovina Bosznia Herzegovina Zászló Bulgária Bulgária Zászló Horvátország Horvátország Zászló Ciprus Ciprus Zászló Montenegró Montenegró Zászló Cseh Köztársaság Cseh Köztársaság Zászló Dánia Dánia Zászló Észtország Észtország Zászló Spanyolország Spanyolország Zászló Koszovó Koszovó Zászló Litvánia Litvánia Zászló Lettország Lettország Zászló Luxemburg Luxemburg Zászló Macedónia Macedónia Zászló Németország Németország Zászló Lengyelország  Lengyelország  Zászló Portugália Portugália Zászló Románia Románia Zászló Szerbia Szerbia Zászló Szlovákia Szlovákia Zászló Szlovénia Szlovénia Zászló Svájc Svájc Zászló Svédország Svédország Zászló Törökország Törökország Zászló Magyarország Magyarország Zászló Egyesült Királyság Egyesült Királyság Zászló Olaszország Olaszország

Ázsia:

Zászló UAE UAE Zászló Hong-Kong Hong-Kong Zászló Kuvait Kuvait Zászló Libanon Libanon

Afrika:

Zászló Dél-Afrika Dél-Afrika
Visszahívást kérek

Szeretne többet megtudni szolgáltasainkról?

Töltse ki az alábbi regisztrációs felületet és kollégáink hamarosan felveszik önnel a kapcsolatot, hogy válaszoljanak minden felmerülő kérdésére

    "Adatait semmilyen körülmények között nem tesszük harmadik fél számára hozzáférhetővé.

    Obraz

    Életmentő
    transzplantációk listája

    A Famicord csoport laboratóriumaiból kezelésre kiadott minták listája.

    Obraz
    Lp. Őssejt forrás Forrás típusa Diagnózis Érintett szakterület Kezelés éve Terápia Ország Páciens életkora
    501 Apheresis Allogeneic Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 62
    502 Apheresis Allogeneic Hodgkin’s Disease Hematology 2026 Standard Therapy Italy 34
    503 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy France 20
    504 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
    505 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 51
    506 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 58
    507 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Ukraine 45
    508 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 41
    509 Apheresis Allogeneic Hodgkin’s Disease Hematology 2026 Standard Therapy Poland 44
    510 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy USA 47
    511 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Colombia 57
    512 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Australia 72
    513 Apheresis Allogeneic EBV-positive nodal T- and NK-cell lymphoma Hematology 2026 Standard Therapy Poland 68
    514 Apheresis Allogeneic Acute Myeloid Leukemia, Myelodysplasia-Related Hematology 2026 Standard Therapy Russia Federation 48
    515 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Finland 69
    516 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 67
    517 Apheresis Allogeneic Large Cell Anaplastic Lyphoma ALK Hematology 2026 Standard Therapy Serbia 13
    518 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
    519 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Lithuania 64
    520 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
    521 Apheresis Allogeneic Acute Undifferentiated Leukemia Hematology 2026 Standard Therapy USA 16
    522 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Czechia 53
    523 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    524 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 18
    525 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 50
    526 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Lithuania 66
    527 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 51
    528 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 41
    529 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 72
    530 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
    531 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 61
    532 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 62
    533 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 62
    534 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Spain 61
    535 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 58
    536 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy India 2
    537 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 21
    538 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 63
    539 Apheresis Autologous Diffuse Large B-cell Lymphoma Hematology 2026 Standard Therapy Germany 71
    540 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 61
    541 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 65
    542 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 64
    543 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
    544 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 59
    545 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 66
    546 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    547 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 53
    548 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy France 26
    549 Apheresis Allogeneic Inherited Metabolic Disorder Hematology 2026 Standard Therapy France 50
    550 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
    551 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 70
    552 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Argentina 30
    553 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 74
    554 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 61
    555 Apheresis Allogeneic Hyper IgE Syndrome Hematology 2026 Standard Therapy Australia 11
    556 Apheresis Allogeneic AML FLT3+ Hematology 2026 Standard Therapy Croatia 61
    557 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 61
    558 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 58
    559 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Iran 3
    560 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 59
    561 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 58
    562 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 10
    563 Apheresis Allogeneic Lymphoma – Peripheral T cell Hematology 2026 Standard Therapy United Kingdom 53
    564 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 48
    565 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Spain 13
    566 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Italy 58
    567 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 69
    568 Apheresis Allogeneic Peripheral T Cell Lymphoma With Haemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy United Kingdom 52
    569 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 62
    570 Apheresis Allogeneic T-Cell Prolymphocytic Leukemia Hematology 2026 Standard Therapy Italy 72
    571 Apheresis Allogeneic Myelodysplastic Disorder Hematology 2026 Standard Therapy Russian Federation 51
    572 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 64
    573 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
    574 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 49
    575 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 75
    576 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    577 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 58
    578 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 52
    579 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 69
    580 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 20
    581 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
    582 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Belgium 34
    583 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
    584 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 69
    585 Apheresis Allogeneic T-Cell Acute lymphoblastic leukemia Hematology 2026 Standard Therapy Netherlands 21
    586 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 70
    587 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 68
    588 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 16
    589 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
    590 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    591 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 65
    592 Apheresis Autologous Central Nervous System Lymphoma Hematology 2026 Standard Therapy Germany 65
    593 Apheresis Autologous Diffuse Large B-cell Lymphoma Hematology 2026 Standard Therapy Germany 45
    594 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    595 Apheresis Allogeneic B-cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 21
    596 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 65
    597 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    598 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 5
    599 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Hungary 57
    600 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 30